Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Akebia Announces Nine Abstracts Accepted for Presentation at the American Society of Nephrology Kidney Week 2019 Annual Meeting

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that nine abstracts, including several associated with vadadustat and Auryxia® (ferric citrate), have been accepted for presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2019 Annual Meeting. ASN Kidney Week 2019 will take place in Washington, D.C. from November 5 to November 10, 2019 at the Walter E. Washington Convention Center. Conference attendees can meet with Company representatives at Booth #2307 to discuss Akebia's presentations.

Four posters and presentations are associated with vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) in global Phase 3 development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis dependent (DD)-CKD patients and non-dialysis dependent (NDD)-CKD patients. All abstracts selected for presentation are summarized below and are available from ASN on the Kidney Week abstracts archive: https://www.asn-online.org/education/kidneyweek/archives/.

Vadadustat Oral and Poster Presentations:

Ferric Citrate and Additional Oral and Poster Presentations:

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

About Vadadustat
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in global Phase 3 development for the treatment of anemia due to CKD. Vadadustat is designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat is an investigational therapy and is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.

About Auryxia® (ferric citrate) Tablets
Auryxia (ferric citrate) was approved by the FDA on September 5, 2014 for the control of serum phosphorus levels in adult patients with CKD on dialysis and approved by the FDA on November 6, 2017 for the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. For more information about Auryxia and the U.S. full prescribing information, please visit www.auryxia.com.

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis.



Most common adverse reactions with AURYXIA were:


To report suspected adverse reactions, contact Akebia Therapeutics at 1-844-445-3799.
Please see full Prescribing Information.

These press releases may also interest you

25 sep 2020
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Vaxart, Inc. . In early 2020, the Company, which focuses on...

25 sep 2020
Century Specialty Script, LLC ("Century"), a specialty pharmacy which provides an array of specific and personalized services in all pharmacy related matters, announced today that it has taken action after learning of a data security incident which...

25 sep 2020
Frog Street, a leading provider of comprehensive early childhood education solutions, has launched multiple new platforms and resources to help early childhood educators and parents navigate the new hybrid at-home learning scenarios for children ages...

25 sep 2020
IDSolutions (IDS), end-to-end telehealth solution provider, and Tryten, manufacturer of healthcare and education carts, announced they are expanding their joint solution offering in healthcare. IDS first teamed up with Tryten in 2018 during the...

25 sep 2020
NASA has selected Space Exploration Technologies (SpaceX) of Hawthorne, California, to provide launch services for the agency's Interstellar Mapping and Acceleration Probe (IMAP) mission, which includes four secondary payloads. IMAP will help...

25 sep 2020
C Spire today unveiled the latest products from Apple on its customer-inspired network, including Apple Watch Series 6, Apple Watch SE and Family Setup, the eighth-generation iPad and redesigned iPad Air. ...

News published on 24 october 2019 at 08:05 and distributed by: